Iberdomide vs TQB3820

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline

Iberdomide · Zenbexus

Marketed by Bristol-Myers Squibb

Approved in Multiple Myelomasmall molecule (CELMoD / cereblon E3 ligase modulator)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT05560399 (registry estimate)

No aligned efficacy figure on record for this race.

TQB3820

Developed by Sino Biopharmaceutical

small molecule
Weak signal

NCT05020639 · Phase 1 · status unknown

This is a single-arm, open-label, non-randomized dose-escalation study designed to determine a tolerable dose rather than to test clinical benefit, with no comparator arm and no blinding. Results have not yet been posted. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIberdomideTQB3820
PFS, median—Trial running · NCT04934475—Not reported
OS, median—Trial running · NCT04934475—Not reported
ORR—Trial running · NCT04934475—Not reported
VGPR or better—Trial running · NCT04934475—Not reported
MRD negativity—Trial running · NCT04934475—Not reported

PFS, median

Iberdomide
—Trial running · NCT04934475
TQB3820
—Not reported

OS, median

Iberdomide
—Trial running · NCT04934475
TQB3820
—Not reported

ORR

Iberdomide
—Trial running · NCT04934475
TQB3820
—Not reported

VGPR or better

Iberdomide
—Trial running · NCT04934475
TQB3820
—Not reported

MRD negativity

Iberdomide
—Trial running · NCT04934475
TQB3820
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Iberdomide: no structured comparison results are available for Multiple Myeloma.

TQB3820: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iberdomide's landscape · TQB3820's landscape